ICCC Quote, Financials, Valuation and Earnings

ACADIA Pharmaceuticals, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of 25.76%. ImmuCell Corp.'s return on equity of 8.15% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 111.16%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 37.49%. Given that ImmuCell Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ImmuCell Corp. is more attractive than ACADIA Pharmaceuticals, Inc..

ImmuCell Corp. has a beta of 0.300, which suggesting that the stock is 70.041% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. ImmuCell Corp.'s net income of -$139.7K is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 25.61x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.15x versus 3.65x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Becton, Dickinson & Co. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of 7.27%. ImmuCell Corp.'s return on equity of 8.15% beat Becton, Dickinson & Co.'s return on equity of 6.94%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 111.16%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $197.17 which suggests that it could grow by 14.85%. Given that ImmuCell Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe ImmuCell Corp. is more attractive than Becton, Dickinson & Co..

ImmuCell Corp. has a beta of 0.300, which suggesting that the stock is 70.041% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.233%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton, Dickinson & Co. offers a yield of 1.91% to investors and pays a quarterly dividend of $0.83 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.3B. ImmuCell Corp.'s net income of -$139.7K is lower than Becton, Dickinson & Co.'s net income of $382M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 25.61x while Becton, Dickinson & Co.'s PE ratio is 28.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.15x versus 2.25x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Cumberland Pharmaceuticals, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of -23.5%. ImmuCell Corp.'s return on equity of 8.15% beat Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 111.16%. On the other hand Cumberland Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 120.21%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than ImmuCell Corp., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than ImmuCell Corp..

ImmuCell Corp. has a beta of 0.300, which suggesting that the stock is 70.041% less volatile than S&P 500. In comparison Cumberland Pharmaceuticals, Inc. has a beta of -0.524, suggesting its less volatile than the S&P 500 by 152.43%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cumberland Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Cumberland Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than Cumberland Pharmaceuticals, Inc. quarterly revenues of $8.3M. ImmuCell Corp.'s net income of -$139.7K is higher than Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 25.61x while Cumberland Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.15x versus 1.38x for Cumberland Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of -1.17%. ImmuCell Corp.'s return on equity of 8.15% beat Precipio, Inc.'s return on equity of -10.15%.

ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 111.16%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -10.25%. Given that ImmuCell Corp. has higher upside potential than Precipio, Inc., analysts believe ImmuCell Corp. is more attractive than Precipio, Inc..

ImmuCell Corp. has a beta of 0.300, which suggesting that the stock is 70.041% less volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.803%.

ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than Precipio, Inc. quarterly revenues of $6.8M. ImmuCell Corp.'s net income of -$139.7K is lower than Precipio, Inc.'s net income of -$79K. Notably, ImmuCell Corp.'s price-to-earnings ratio is 25.61x while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 2.15x versus 1.45x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.